{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:05:19Z","timestamp":1764785119508,"version":"3.37.3"},"reference-count":36,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"DOI":"10.13039\/501100014996","name":"Health Bureau of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY813"],"award-info":[{"award-number":["2021KY813"]}],"id":[{"id":"10.13039\/501100014996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013254","name":"National College Students' innovation and entrepreneurship training program","doi-asserted-by":"publisher","award":["202110344032"],"award-info":[{"award-number":["202110344032"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Liver fibrosis usually progresses to liver cirrhosis and even results in hepatocellular\ncarcinoma, which accounts for one million deaths annually worldwide. To date, anti-liver fibrosis\ndrugs for clinical treatment have not yet been approved. Nowadays, as a natural regulator, Relaxin\n(RLX) has received increased attention because the expression of RLX could deactivate the activation\nof hepatic stellate cells (aHSCs) and resolve liver fibrosis. However, its application in treatment is limited\ndue to the short half-life in circulation and low accumulation within the target organ.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>To address these problems, a kind of polymeric metformin (PolyMet)-loaded relaxin plasmid\n(pRLX) core-membrane lipid nanoparticle (PolyMet-pRLX-LNPs, PRLNP) was prepared. Here,\nPolyMet was used as a carrier to replace the traditional polymer polyethylene diene (PEI), which is of\nhigher toxicity, to prolong the circulation time of pRLX in vivo. Then, the antifibrotic ability of PRLNP\nto overcome liver fibrosis was carried out in C57BL\/6 mice. It is worth mentioning that this is the first\ntime to investigate the potential of PRLNP in carbon tetrachloride-induced liver fibrosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The results showed that PRLNP effectively downregulated fibrosis-related biomarkers such as\nalanine aminotransferase (ALT) and aspartate aminotransferase (AST). Meanwhile, histopathological\nexaminations also showed low collagen accumulation, revealing that PRLNP could histologically and\nfunctionally alleviate liver fibrosis. In addition, no significant difference in serum biochemical value\nbetween the PRLNP and the normal group, suggesting the safety profile of PRLNP.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This research proposed a novel non-toxic treatment method for liver fibrosis with a nanosystem\nto effectively treat liver fibrosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567201820666230407135026","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T04:59:55Z","timestamp":1681102795000},"page":"431-437","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Delivering Relaxin Plasmid by Polymeric Metformin Lipid Nanoparticles\nfor Liver Fibrosis Treatment"],"prefix":"10.2174","volume":"21","author":[{"given":"Yujie","family":"Li","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisha","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"},{"name":"Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"},{"name":"Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbin","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"},{"name":"Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Chai","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengshan","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/cells10102759","volume":"10","author":"Caligiuri A.","year":"2021","unstructured":"Caligiuri A.; Gentilini A.; Pastore M.; Gitto S.; Marra F.; Cellular and molecular mechanisms underlying liver fibrosis regression. Cells 2021,10(10),2759","journal-title":"Cells"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","volume":"71","author":"Xiao J.","year":"2019","unstructured":"Xiao J.; Wang F.; Wong N.K.; He J.; Zhang R.; Sun R.; Xu Y.; Liu Y.; Li W.; Koike K.; He W.; You H.; Miao Y.; Liu X.; Meng M.; Gao B.; Wang H.; Li C.; Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol 2019,71(1),212-221","journal-title":"J Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"Asrani S.K.","year":"2019","unstructured":"Asrani S.K.; Devarbhavi H.; Eaton J.; Kamath P.S.; Burden of liver diseases in the world. J Hepatol 2019,70(1),151-171","journal-title":"J Hepatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"Tsuchida T.","year":"2017","unstructured":"Tsuchida T.; Friedman S.L.; Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017,14(7),397-411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"116887","DOI":"10.1016\/j.carbpol.2020.116887","volume":"249","author":"Luo J.","year":"2020","unstructured":"Luo J.; Gong T.; Ma L.; Chondroitin-modified lipid nanoparticles target the Golgi to degrade extracellular matrix for liver cancer management. Carbohydr Polym 2020,249,116887","journal-title":"Carbohydr Polym"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1053\/j.gastro.2019.07.036","volume":"157","author":"Fan W.","year":"2019","unstructured":"Fan W.; Liu T.; Chen W.; Hammad S.; Longerich T.; Hausser I.; Fu Y.; Li N.; He Y.; Liu C.; Zhang Y.; Lian Q.; Zhao X.; Yan C.; Li L.; Yi C.; Ling Z.; Ma L.; Zhao X.; Xu H.; Wang P.; Cong M.; You H.; Liu Z.; Wang Y.; Chen J.; Li D.; Hui L.; Dooley S.; Hou J.; Jia J.; Sun B.; ECM1 prevents activation of transforming growth factor \u03b2 hepatic stellate cells, and fibrogenesis in mice. Gastroenterology 2019,157(5),1352-1367.e13","journal-title":"Gastroenterology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41419-020-2596-8","volume":"11","author":"Sun W.Y.","year":"2020","unstructured":"Sun W.Y.; Gu, Y.J.; Li, X.R.; Sun, J.C.; Du, J.J.; Chen, J.Y.; Ma, Y.; Wang, Q.T.; Wei, W. \u03b2-arrestin2 deficiency protects against hepatic fibrosis in mice and prevents synthesis of extracellular matrix. Cell Death Dis 2020,11(5),389","journal-title":"Cell Death Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"Kisseleva T.","year":"2021","unstructured":"Kisseleva T.; Brenner D.; Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 2021,18(3),151-166","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2015.11.003","volume":"221","author":"Lin T.T.","year":"2016","unstructured":"Lin T.T.; Gao D.Y.; Liu Y.C.; Sung Y.C.; Wan D.; Liu J.Y.; Chiang T.; Wang L.; Chen Y.; Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Control Release 2016,221,62-70","journal-title":"J Control Release"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.3390\/ijms160510624","volume":"16","author":"Kim J.","year":"2015","unstructured":"Kim J.; Jung Y.; Potential role of thymosin Beta 4 in liver fibrosis. Int J Mol Sci 2015,16(12),10624-10635","journal-title":"Int J Mol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fimmu.2020.00480","volume":"11","author":"Klepfish M.","year":"2020","unstructured":"Klepfish M.; Gross T.; Vugman M.; Afratis N.A.; Havusha-Laufer S.; Brazowski E.; Solomonov I.; Varol C.; Sagi I.; LOXL2 inhibition paves the way for macrophage-mediated collagen degradation in liver fibrosis. Front Immunol 2020,11,480","journal-title":"Front Immunol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jconrel.2020.01.042","volume":"320","author":"Han H.S.","year":"2020","unstructured":"Han H.S.; Lee H.; You D.; Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis. J Control Release 2020,320,328-336","journal-title":"J Control Release"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1080\/10408398.2014.952399","volume":"57","author":"Van De Wier B.","year":"2017","unstructured":"Van De Wier B.; Koek G.H.; Bast A.; Haenen G.R.M.M.; The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr 2017,57(4),834-855","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","volume":"12","author":"Zimmermann G.R.","year":"2007","unstructured":"Zimmermann G.R.; Leh\u00e1r J.; Keith C.T.; Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007,12(1-2),34-42","journal-title":"Drug Discov Today"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","volume":"62","author":"Trautwein C.","year":"2015","unstructured":"Trautwein C.; Friedman S.L.; Schuppan D.; Pinzani M.; Hepatic fibrosis: Concept to treatment. J Hepatol 2015,62(Suppl. 1),S15-S24","journal-title":"J Hepatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41467-019-10893-8","volume":"10","author":"Hu M.","year":"2019","unstructured":"Hu M.; Wang Y.; Xu L.; An S.; Tang Y.; Zhou X.; Li J.; Liu R.; Huang L.; Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nat Commun 2019,10(1),2993","journal-title":"Nat Commun"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41374-019-0240-y","volume":"99","author":"Lee K.C.","year":"2019","unstructured":"Lee K.C.; Hsieh Y.C.; Chan C.C.; Sun H.J.; Huang Y.H.; Hou M.C.; Lin H.C.; Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. Lab Invest 2019,99(8),1203-1216","journal-title":"Lab Invest"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/bph.13529","volume":"174","author":"Samuel C.S.","year":"2017","unstructured":"Samuel C.S.; Royce S.G.; Hewitson T.D.; Denton K.M.; Cooney T.E.; Bennett R.G.; Anti\u2010fibrotic actions of relaxin. Br J Pharmacol 2017,174(10),962-976","journal-title":"Br J Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/hep.26627","volume":"59","author":"Fallowfield J.A.","year":"2014","unstructured":"Fallowfield J.A.; Hayden A.L.; Snowdon V.K.; Aucott R.L.; Stutchfield B.M.; Mole D.J.; Pellicoro A.; Gordon-Walker T.T.; Henke A.; Schrader J.; Trivedi P.J.; Princivalle M.; Forbes S.J.; Collins J.E.; Iredale J.P.; Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology 2014,59(4),1492-1504","journal-title":"Hepatology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/bph.13778","volume":"174","author":"Summers R.J.","year":"2017","unstructured":"Summers R.J.; Recent progress in the understanding of relaxin family peptides and their receptors. Br J Pharmacol 2017,174(10),915-920","journal-title":"Br J Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41565-020-00832-w","volume":"16","author":"Fallowfield J.A.","year":"2021","unstructured":"Fallowfield J.A.; Ramachandran P.; A relaxin-based nanotherapy for liver fibrosis. Nat Nanotechnol 2021,16(4),365-366","journal-title":"Nat Nanotechnol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.09.031","volume":"290","author":"Mardhian D.F.","year":"2018","unstructured":"Mardhian D.F.; Storm G.; Bansal R.; Prakash J.; Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Control Release 2018,290,1-10","journal-title":"J Control Release"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/gutjnl-2016-312869","volume":"67","author":"Hanin G.","year":"2018","unstructured":"Hanin G.; Yayon N.; Tzur Y.; Haviv R.; Bennett E.R.; Udi S.; Krishnamoorthy Y.R.; Kotsiliti E.; Zangen R.; Efron B.; Tam J.; Pappo O.; Shteyer E.; Pikarsky E.; Heikenwalder M.; Greenberg D.S.; Soreq H.; miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut 2018,67(6),1124-1134","journal-title":"Gut"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"12435","DOI":"10.1096\/fj.201901046R","volume":"33","author":"Kaftanovskaya E.M.","year":"2019","unstructured":"Kaftanovskaya E.M.; Ng H.H.; Soula M.; Rivas B.; Myhr C.; Ho B.A.; Cervantes B.A.; Shupe T.D.; Devarasetty M.; Hu X.; Xu X.; Patnaik S.; Wilson K.J.; Barnaeva E.; Ferrer M.; Southall N.T.; Marugan J.J.; Bishop C.E.; Agoulnik I.U.; Agoulnik A.I.; Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J 2019,33(11),12435-12446","journal-title":"FASEB J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nano.2018.12.008","volume":"17","author":"Nag\u00f3rniewicz B.","year":"2019","unstructured":"Nag\u00f3rniewicz B.; Mardhian D.F.; Booijink R.; Storm G.; Prakash J.; Bansal R.; Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis. Nanomedicine 2019,17,106-118","journal-title":"Nanomedicine"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41565-020-00836-6","volume":"16","author":"Hu M.","year":"2021","unstructured":"Hu M.; Wang Y.; Liu Z.; Yu Z.; Guan K.; Liu M.; Wang M.; Tan J.; Huang L.; Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nat Nanotechnol 2021,16(4),466-477","journal-title":"Nat Nanotechnol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"Yin H.","year":"2014","unstructured":"Yin H.; Kanasty R.L.; Eltoukhy A.A.; Vegas A.J.; Dorkin J.R.; Anderson D.G.; Non-viral vectors for gene-based therapy. Nat Rev Genet 2014,15(8),541-555","journal-title":"Nat Rev Genet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"Shirley J.L.","year":"2020","unstructured":"Shirley J.L.; de Jong Y.P.; Terhorst C.; Herzog R.W.; Immune responses to viral gene therapy vectors. Mol Ther 2020,28(3),709-722","journal-title":"Mol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2147\/IJN.S222419","volume":"15","author":"Chen C.K.","year":"2020","unstructured":"Chen C.K.; Huang P.K.; Law W.C.; Chu C.H.; Chen N.T.; Lo L.W.; Biodegradable polymers for gene-delivery applications. Int J Nanomedicine 2020,15,2131-2150","journal-title":"Int J Nanomedicine"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.critrevonc.2013.10.006","volume":"89","author":"Sun N.","year":"2014","unstructured":"Sun N.; Liu Z.; Huang W.; Tian A.; Hu S.; The research of nanoparticles as gene vector for tumor gene therapy. Crit Rev Oncol Hematol 2014,89(3),352-357","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"Boussif O.","year":"1995","unstructured":"Boussif O.; Lezoualc\u2019h F.; Zanta M.A.; Mergny M.D.; Scherman D.; Demeneix B.; Behr J.P.; A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci 1995,92(16),7297-7301","journal-title":"Proc Natl Acad Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jconrel.2014.05.055","volume":"193","author":"Islam M.A.","year":"2014","unstructured":"Islam M.A.; Park T.E.; Singh B.; Maharjan S.; Firdous J.; Cho M.H.; Kang S.K.; Yun C.H.; Choi Y.J.; Cho C.S.; Major degradable polycations as carriers for DNA and siRNA. J Control Release 2014,193,74-89","journal-title":"J Control Release"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0168-3659(99)00090-5","volume":"60","author":"Godbey W.T.","year":"1999","unstructured":"Godbey W.T.; Wu K.K.; Mikos A.G.; Poly(ethylenimine) and its role in gene delivery. J Control Release 1999,60(2-3),149-160","journal-title":"J Control Release"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"Lv H.","year":"2006","unstructured":"Lv H.; Zhang S.; Wang B.; Cui S.; Yan J.; Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006,114(1),100-109","journal-title":"J Control Release"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2016.11.005","volume":"244","author":"Xiong Y","year":"2016","unstructured":"Xiong Y; Zhao Y; Miao L; Lin CM; Huang L; Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles\tto treat non-small cell lung cancer. J Control Release 2016,244(Pt A),63-73","journal-title":"J Control Release"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"11822","DOI":"10.1038\/ncomms11822","volume":"7","author":"Zhao Y.","year":"2016","unstructured":"Zhao Y.; Wang W.; Guo S.; Wang Y.; Miao L.; Xiong Y.; Huang L.; PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nat Commun 2016,7(1),11822","journal-title":"Nat Commun"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201820666230407135026","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215554\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567201820666230407135026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T11:23:55Z","timestamp":1700652235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215554\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201820666230407135026","relation":{},"ISSN":["1567-2018"],"issn-type":[{"type":"print","value":"1567-2018"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}